Coronary artery bypass grafting vascular grafts restenosis prevention system

Abstract

The invention provides a coronary artery bypass grafting vascular grafts restenosis prevention system, which comprises a saccule and PLGA (poly(lactic-co-glycolic acid) nanometer particles, with fluvastatin, contained in the saccule. A taxol coating coats the surface of the saccule; and micropores are formed in the side wall of the saccule. By aiming at the postoperative long-period smoothness rate influence major factors of coronary artery bypass grafting, i.e., the problems of postoperative medium-period hyperplasia endometrii, long-period Endothelial atherosclerosis and the like, the invention designs the coronary artery bypass grafting vascular grafts restenosis prevention system. The saccules with different diameters are selected according to the vein diameter; then, PLGA microspheres are pushed in from an injector, so that composite medicine of heparin, paclitaxel and fluvastatin composite medicine enters the artery blood vessel; and the postoperative long-period smoothness rate is improved.

Description

technical field [0001] The invention belongs to the field of medical instruments, in particular to a surgical instrument used in coronary artery bypass grafting. Background technique [0002] As the main grafting material, vein graft is widely used clinically, but its long-term patency rate seriously affects the long-term curative effect of CABG (coronary artery bypass grafting). The research results on the pathological basis of restenosis after saphenous vein surgery show that there are different manifestations of restenosis in the early, middle and late stages, including: [0003] (1) Early manifestations. In the early stage (1 month after operation), it is mainly due to thrombosis, improper operations such as pulling and clamping in the process of material collection and vascular anastomosis, and excessive force can lead to venous endothelial injury, 15% to 18% of graft vein thrombosis can be attributed to this. At the same time, the sudden increase in the pressure in t...

AI Technical Summary

Problems solved by technology

[0007] 1. Oral and intravenous medication. At present, oral aspirin + ticagrelor double anticoagulant can effectively improve the patency rate after bypass surgery, but the incidence of vein graft restenosis is still as high as 10%, and it cannot be corrected. etiology of restenosis

For patients with poor vascular conditions or intraoperative coronary endarterectomy, intravenous heparin can be injected to inhibit thrombosis in graft vessels after surgery, but intravenous heparin can only inhibit perioperative thrombosis but cannot inhibit long-term graft vessel formation Atherosclerosis, and prone to postoperative hemorrhagic complications

[0008] 2. Improved expansion fluid. The expansion of the saphenous vein after extraction has become a routine operation in CABG. At present, most of the commonly used saphenous vein expansion fluids are simple heparin saline, which only has a simple dilation effect.

With the revelation of the human gene map, gene therapy for restenosis of vein grafts after CABG has become a hot topic, and some studies have also confirmed its feasibility, but it still faces the problem of how to select the appropriate gene carrier and have therapeutic value. Two big problems with genes

Images